Medicenna Therapeutics (TSE:MDNA) Hits New 52-Week Low – Time to Sell?

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.42 and last traded at C$0.41, with a volume of 87461 shares. The stock had previously closed at C$0.41.

Medicenna Therapeutics Stock Up 3.6%

The company has a market capitalization of C$35.87 million, a P/E ratio of -2.87 and a beta of 2.89. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68. The firm’s fifty day moving average is C$0.53 and its 200-day moving average is C$0.79.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings data on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. As a group, equities research analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.